Bone morphogenetic protein-7 and Gremlin: New emerging therapeutic targets for diabetic nephropathy

Biochem Biophys Res Commun. 2009 May 22;383(1):1-3. doi: 10.1016/j.bbrc.2009.03.086. Epub 2009 Mar 19.

Abstract

Specific therapies of diabetic nephropathy (DN) are not available, and current treatment strategies are limited to management of blood glucose levels and control of hypertension. The re-activation of developmental programs in DN suggests new potential therapeutic targets. Bone morphogenetic protein-7 (BMP-7) and its antagonist, Gremlin is revealed to be involved in renal development and diabetic nephropathy. This article reviews the changes of BMP-7 and Gremlin in diabetic kidney, the protective effects on diabetic nephropathy when targeting BMP-7 and Gremlin, and the possible mechanism. The reorganization of the re-activation of Gremlin and BMP-7 in diabetic kidney had shed light on the identification of novel therapeutic targets for DN.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bone Morphogenetic Protein 7 / agonists
  • Bone Morphogenetic Protein 7 / antagonists & inhibitors
  • Bone Morphogenetic Protein 7 / metabolism*
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / metabolism
  • Humans
  • Intercellular Signaling Peptides and Proteins / genetics
  • Intercellular Signaling Peptides and Proteins / metabolism*
  • Mice

Substances

  • Bone Morphogenetic Protein 7
  • GREM1 protein, human
  • Intercellular Signaling Peptides and Proteins